Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2007

View Archived Issues

Takeda presents first quarter results for 2008

Cognition enhancement effects of A-412997, a D4 receptor agonist, reported

Canopus reports preclinical trials results of influenza antiviral drug StatC

Rectally delivered HIV vaccine immunogenic in preclinical studies

New treatment options for cardiovascular disorders disclosed in recent patents

Various types of novel oncolytic compounds described in recent patent literature

New agents for respiratory disorders disclosed in recent Japanese patent

Central effects of adiponectin on food intake elucidated

Bionomics to develop BNO69 inhibitors for cancer

FDA accepts Solvay's responses to approvable letters for Luvox CR and Luvox

Axcan Pharma submits complete NDA for Ultrase

Long-term use of Isotechnika's ISA-247 in phase IIb trial allowed by FDA

Unigene begins clinical study of oral calcitonin for osteoporosis

Update on Prana's phase IIa trial of PBT-2 for Alzheimer's disease

Hisamitsu acquires exclusive sales and distribution rights for Norspan for Japan

Patient enrollment for TorreyPines' phase IIb tezampanel trial completed

SkyePharma provides Flutiform progress update

Encysive files request for formal dispute resolution with FDA

Top-line results for MicroDose's glucose clamp study of QDose insulin inhaler

Anadis and ImmuCell sign heads of agreement for antibody technologies

Biovitrum and Wyeth to copromote BeneFIX in Nordic countries

Dynavax receives grant from NIAID to develop a universal flu vaccine

ImmuneRegen BioSciences finalizes material transfer agreement with VaxGen

New magnetic resonance imaging agent, a promising tool for Alzheimer's disease diagnosis

Betaseron treatment in the early phase of MS protects against confirmed disability

Archemix allies with Isis, SomaLogic for aptamer drug discovery and development

Novacta Biosystems receives funding for antiinfective agents for C. difficile

Tercica granted marketing approval for Increlex in the E.U.

Positive preclinical results from Quark's RNAi compound in acute renal failure

LEO Pharma enrolls first patient in phase II study of ATryn in DIC indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...